strategies for in vivo screening and mitigation of hepatotoxicity associated with antisense drugs
Clicks: 189
ID: 162821
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
189 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #65 of 77 articles by views in coordination chemistry reviews
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Antisense oligonucleotide (ASO) gapmers downregulate gene expression by inducing enzyme-dependent degradation of targeted RNA and represent a promising therapeutic platform for addressing previously undruggable genes. Unfortunately, their therapeutic application, particularly that of the more potent chemistries (e.g., locked-nucleic-acid-containing gapmers), has been hampered by their frequent hepatoxicity, which could be driven by hybridization-mediated interactions. An early de-risking of this liability is a crucial component of developing safe, ASO-based drugs. To rank ASOs based on their effect on the liver, we have developed an acute screen in the mouse that can be applied early in the drug development cycle. A single-dose (3-day) screen with streamlined endpoints (i.e., plasma transaminase levels and liver weights) was observed to be predictive of ASO hepatotoxicity ranking established based on a repeat-dose (15 day) study. Furthermore, to study the underlying mechanisms of liver toxicity, we applied transcriptome profiling and pathway analyses and show that adverse in vivo liver phenotypes correlate with the number of potent, hybridization-mediated off-target effects (OTEs). We propose that a combination of in silico OTE predictions, streamlined in vivo hepatotoxicity screening, and a transcriptome-wide selectivity screen is a valid approach to identifying and progressing safer compounds. Keywords: antisense oligonucleotides, ASOs, off-target effects, OTEs, hepatotoxicity, locked nucleic acids, LNA, gene silencing, RNArcher, selectivity
| Reference Key |
kamola2017molecularstrategies
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Piotr J. Kamola;Klio Maratou;Paul A. Wilson;Kay Rush;Tanya Mullaney;Tom McKevitt;Paula Evans;Jim Ridings;Probash Chowdhury;Aude Roulois;Ann Fairchild;Sean McCawley;Karen Cartwright;Nigel J. Gooderham;Timothy W. Gant;Kitty Moores;Stephen A. Hughes;Mark R. Edbrooke;Kenneth Clark;Joel D. Parry |
| Journal | coordination chemistry reviews |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.